Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership
Research on ownership and analyst forecasts data are crucial in understanding stock opportunities. Institutions hold a significant stake in Relmada Therapeutics, influencing its performance. Analysts and ownership data help predict a stock's future growth potential.